Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
PMCID: PMC11397063
Response: We recognize the value of measures undergoing testing and evaluation of reliability, feasibility, and validity in the setting for which they are being adopted
If you do not agree to the terms and conditions, you may not access or use the software
Drug exposure The study cohort consisted of new users of GLP-1RAs (dulaglutide, exenatide, liraglutide, lixisenatide or semaglutide), SGLT2 inhibitors (canagliflozin, dapagliflozin or empagliflozin), metformin and other second- or third-line glucose-lowering drugs (thiazolidinediones, dipeptidyl peptidase-4 inhibitors, sulfonylureas, meglitinides, -glucosidase inhibitors, insulin or a combination of glucose-lowering drugs)
US$ 26.38
US$ 24.49
US$ 22.79
